Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review

被引：0
|
作者：
Francesco Spagnolo
Andrea Boutros
Federica Cecchi
Elena Croce
Enrica Teresa Tanda
Paola Queirolo
机构：
[1] IRCCS Ospedale Policlinico San Martino,Medical Oncology 2
[2] European Institute of Oncology (IEO),Melanoma, Sarcoma & Rare Tumors Division
来源：
BMC Cancer | / 21卷
关键词：
Melanoma; Immunotherapy; Immune-related response criteria; Treatment beyond progression; Anti-PD-1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Dostarlimab Anti-PD-1 monoclonal antibody Treatment of advanced solid tumors
    Haddley, K.
    DRUGS OF THE FUTURE, 2019, 44 (07) : 527 - 534
  • [22] The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
    Sui, Xinbing
    Ma, Junhong
    Han, Weidong
    Wang, Xian
    Fang, Yong
    Li, Da
    Pan, Hongming
    Zhang, Li
    ONCOTARGET, 2015, 6 (23) : 19393 - 19404
  • [23] PD-1/PD-L1 IMMUNOTHERAPY IS EFFECTIVE IN ADVANCED SOLID TUMORS
    不详
    CANCER DISCOVERY, 2012, 2 (07) : 581 - 581
  • [24] Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis
    Inoue, Takashi
    Narukawa, Mamoru
    CANCER CONTROL, 2022, 29
  • [25] Pneumonitis From Anti-PD-1/PD-L1 Therapy
    Balaji, Aanika
    Verde, Franco
    Suresh, Karthik
    Naidoo, Jarushka
    ONCOLOGY-NEW YORK, 2017, 31 (10): : 739 - +
  • [26] Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis
    Liu, Haoran
    Ye, Tao
    Yang, Xiaoqi
    Lv, Peng
    Wu, Xiaoliang
    Thou, Hui
    Lu, Hongyan
    Tang, Kun
    Ye, Zhangqun
    DISEASE MARKERS, 2020, 2020
  • [27] PREDICTIVE AND PROGNOSTIC ROLE OF PD-L1 IN UROTHELIAL CARCINOMA PATIENTS WITH ANTI-PD-1/PD-L1 THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Tang, Kun
    Jiang, Kehua
    Zhou, Hui
    Liu, Haoran
    Ye, Zhangqun
    Xu, Hua
    JOURNAL OF UROLOGY, 2018, 199 (04): : E1040 - E1040
  • [28] Discontinuation of Anti-PD-1/PD-L1 Antibody Therapy in the Absence of Disease Progression: Clinical Outcomes in Advanced NSCLC
    Minatta, N.
    Bluthgen, M.
    Rizzo, M.
    Rizzi, M.
    Kuzminin, A.
    Recondo, G., Jr.
    Faura, M.
    Naveira, M.
    Perfetti, A.
    Cerini, M.
    Lupinacci, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S741 - S742
  • [29] PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis
    Abdel-Rahman, Omar
    IMMUNOTHERAPY, 2016, 8 (09) : 1081 - 1090
  • [30] Clinical benefit of neoadjuvant anti-PD-1/PD-L1 utilization among different tumors
    Li, Zhiyang
    Wu, Xin
    Zhao, Yanjie
    Xiao, Yinan
    Zhao, Yunuo
    Zhang, Ting
    Li, Hui
    Sha, Fushen
    Wang, Yating
    Deng, Lei
    Ma, Xuelei
    MEDCOMM, 2021, 2 (01): : 60 - 68
12345